Bone marrow stem cells (BMSCs), including hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), play a crucial role in tissue regeneration, immune function, and hematopoiesis. However, with aging, these stem cells undergo cellular senescence, leading to functional decline and increased susceptibility to diseases such as bone marrow failure, myelodysplastic syndromes, and leukemia. Identifying senescence markers in BMSCs is essential for understanding aging mechanisms and developing therapeutic interventions.
Cellular senescence is a state of irreversible cell cycle arrest triggered by various stressors, including DNA damage, oxidative stress, and telomere shortening. Senescent cells exhibit distinct morphological and molecular changes, such as enlarged and flattened morphology, increased senescence-associated β-galactosidase (SA-β-gal) activity, and secretion of pro-inflammatory cytokines (senescence-associated secretory phenotype, SASP).
A widely used biomarker for detecting senescent cells.
Increased activity at pH 6.0 due to lysosomal enlargement in senescent BMSCs.
p16^INK4a: A cyclin-dependent kinase inhibitor (CDKN2A) that induces cell cycle arrest by inhibiting CDK4/6. Elevated p16 levels are strongly associated with aging in HSCs and MSCs.
p21^CIP1/WAF1: A downstream effector of p53, upregulated in response to DNA damage, leading to cell cycle arrest.
γ-H2AX (phosphorylated histone H2AX): A marker of DNA double-strand breaks, commonly elevated in senescent BMSCs.
53BP1 and p-ATM/ATR: DNA damage repair proteins that accumulate in aged stem cells.
Telomeres progressively shorten with each cell division due to insufficient telomerase activity (except in highly proliferative cells like cancer stem cells).
Critically short telomeres trigger senescence via the p53-p21 pathway.
Senescent BMSCs secrete pro-inflammatory cytokines, chemokines, and matrix metalloproteinases (MMPs), including:
IL-6, IL-8, TNF-α: Promote chronic inflammation (inflammaging).
MMP-3, MMP-9: Contribute to extracellular matrix remodeling.
TGF-β: Induces fibrosis and impairs stem cell function.
Increased ROS production leads to oxidative stress, accelerating senescence.
Declined mitochondrial membrane potential (ΔΨm) and reduced ATP production are common in aged BMSCs.
DNA methylation changes: Hypermethylation of promoters (e.g., p16) and global hypomethylation.
Histone modifications: Loss of H3K9me3 and H3K27me3, associated with heterochromatin destabilization.
Reduced self-renewal and differentiation capacity: Impaired hematopoietic and stromal support functions.
Increased inflammation: SASP contributes to age-related diseases like osteoporosis and myelodysplasia.
Clonal expansion of mutated stem cells: Higher risk of hematologic malignancies.
Senolytics: Drugs (e.g., dasatinib + quercetin) that selectively eliminate senescent cells.
Senomorphics: Inhibit SASP (e.g., JAK/STAT inhibitors).
Telomerase activation: Experimental approaches to delay telomere attrition.
Antioxidants: Reduce ROS-induced damage (e.g., N-acetylcysteine).
Senescence markers in bone marrow stem cells provide critical insights into aging and age-related diseases. Targeting these markers with senotherapeutic approaches could rejuvenate stem cell function and improve hematopoietic health. Further research is needed to develop precise interventions for clinical applications.
López-Otín et al. (2013). The Hallmarks of Aging. Cell.
Childs et al. (2015). Cellular Senescence in Aging and Age-Related Disease. Nature Medicine.
Janzen et al. (2006). *Stem-Cell Ageing Modified by the Cyclin-Dependent Kinase Inhibitor p16INK4a*. Nature.
